Published at Tuesday, April 7, 2020 12:34 PM on the Inflection Biosciences Ltd organization's page
Inflection Biosciences CEO interviewed at BIO CEO Investor Conference 2020
Darren Cunningham, CEO Inflection Biosciences, spoke with Christine Corrado from Proactive Investors about the potential for its first-in-class IBL-202 program for CLL and other B-cell malignancies.